DY 301

Drug Profile

DY 301

Alternative Names: Iodine lecithin; L-LBI; Licorice-lecithin bound iodine; Liquorice-lecithin bound iodine

Latest Information Update: 27 Dec 2000

Price : $50

At a glance

  • Originator Daiichi Pharmaceutical
  • Developer Daiichi Pharmaceutical; Nagasaki University School of Medicine; Toho University School of Medicine
  • Class Antiasthmatics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 27 Dec 2000 Discontinued-Clinical for Asthma in Japan (PO)
  • 05 Aug 1996 Investigation in Asthma in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top